anticancer therapy (Philogen/Pfizer)

N/A

Report date: 2025/03/14 16:38:47

Base Information

Drug Nameanticancer therapy (Philogen/Pfizer)
Drug Alias NameF8-IL-2 antibody drug conjugate (Philogen/Pfizer)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItaly
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPhilogen Spa
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPhilogen Spa
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A